PharmaCyte Biotech, Inc. (PMCB)
PMCB Stock Price Chart
Explore PharmaCyte Biotech, Inc. interactive price chart. Choose custom timeframes to analyze PMCB price movements and trends.
PMCB Company Profile
Discover essential business fundamentals and corporate details for PharmaCyte Biotech, Inc. (PMCB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jan 2013
Employees
2.00
Website
https://pharmacyte.comCEO
Joshua N. Silverman
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
PMCB Financial Timeline
Browse a chronological timeline of PharmaCyte Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Mar 2026
Upcoming earnings on 11 Dec 2025
Upcoming earnings on 15 Sept 2025
Earnings released on 17 Mar 2025
EPS came in at -$0.10 .
Earnings released on 13 Dec 2024
EPS came in at -$0.29 .
Earnings released on 16 Sept 2024
EPS came in at $0.14 .
Earnings released on 13 Aug 2024
EPS came in at -$0.85 .
Earnings released on 18 Mar 2024
EPS came in at -$0.65 .
Earnings released on 15 Dec 2023
EPS came in at -$0.64 .
Earnings released on 18 Sept 2023
EPS came in at -$0.28 .
Earnings released on 31 Jul 2023
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%.
Earnings released on 16 Mar 2023
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%.
Earnings released on 14 Dec 2022
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 14 Sept 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 28 Jul 2022
EPS came in at -$0.06 falling short of the estimated -$0.03 by -74.98%.
Earnings released on 15 Mar 2022
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 14 Dec 2021
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 14 Sept 2021
EPS came in at -$0.64 .
Earnings released on 10 Aug 2021
EPS came in at -$0.62 .
Stock split effective on 12 Jul 2021
Shares were split 1 : 1550 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Mar 2021
EPS came in at -$0.49 .
Earnings released on 11 Dec 2020
EPS came in at -$0.62 .
PMCB Stock Performance
Access detailed PMCB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.